Lenzilumab (LENZ)
Chronic Myelomonocytic Leukemia (CMML)
Key Facts
About Taran Therapeutics
Taran Therapeutics is a clinical-stage biotech developing lenzilumab, a monoclonal antibody targeting GM-CSF to treat serious myeloid leukemias and inflammatory conditions. Its lead program is in a fully enrolled Phase 2/3 trial for high-risk CMML, demonstrating an 80% clinical response rate when added to standard of care, significantly outperforming current treatments. The company is also advancing LENZ for secondary AML, MDS, and to mitigate CAR-T therapy toxicities, with a Phase 3 protocol for the latter indication agreed with the FDA. Taran is privately held and preparing for regulatory discussions to chart a path to potential marketing approval.
View full company profileAbout Taran Therapeutics
Taran Therapeutics is a clinical-stage biotech developing lenzilumab, a monoclonal antibody targeting GM-CSF to treat serious myeloid leukemias and inflammatory conditions. Its lead program is in a fully enrolled Phase 2/3 trial for high-risk CMML, demonstrating an 80% clinical response rate when added to standard of care, significantly outperforming current treatments. The company is also advancing LENZ for secondary AML, MDS, and to mitigate CAR-T therapy toxicities, with a Phase 3 protocol for the latter indication agreed with the FDA. Taran is privately held and preparing for regulatory discussions to chart a path to potential marketing approval.
View full company profileAbout Taran Therapeutics
Taran Therapeutics is a clinical-stage biotech developing lenzilumab, a monoclonal antibody targeting GM-CSF to treat serious myeloid leukemias and inflammatory conditions. Its lead program is in a fully enrolled Phase 2/3 trial for high-risk CMML, demonstrating an 80% clinical response rate when added to standard of care, significantly outperforming current treatments. The company is also advancing LENZ for secondary AML, MDS, and to mitigate CAR-T therapy toxicities, with a Phase 3 protocol for the latter indication agreed with the FDA. Taran is privately held and preparing for regulatory discussions to chart a path to potential marketing approval.
View full company profileTherapeutic Areas
Other Chronic Myelomonocytic Leukemia (CMML) Drugs
| Drug | Company | Phase |
|---|---|---|
| STX-0712 | Solu Therapeutics | Phase 1 |
| ELZONRIS (tagraxofusp) | Stemline Therapeutics | Clinical Trials |
| Tipifarnib | Kura Oncology | Phase 2 |
| Onvansertib (Single Agent) | Cardiff Oncology | Phase 2 |